General Hospital Psychiatry
July 24, 2025
Shizhen Wang, Mengru Wu, Jixiang Wei et al.
6 citations
Electronic mindfulness-based cognitive therapy (eMBCT) reduces anxiety and depression in adults with small but significant effects that are sustained over time. A meta-analysis of 12 randomized controlled trials with 2,588 participants found that eMBCT lowered anxiety (standardized mean difference -0.33) and depression (-0.34) compared to usual care, waitlist, or active interventions. Greater baseline symptom severity was linked to larger improvements. Short- and long-term benefits were observed, but medium-term effects were not significant. The findings suggest eMBCT is an effective scalable treatment, though further research is needed to enhance medium- and long-term outcomes and tailor interventions for flexible patient care.
General Hospital Psychiatry
January 1, 2025
Shizhen Wang, Wangjie Xia, Jian Zhang et al.
6 citations
A meta-analysis of 10 randomized controlled trials with 1314 cancer patients found that internet-based mindfulness interventions reduce anxiety and depression. The interventions were most effective when sessions lasted under 45 minutes and the program duration was within 8 weeks. Therapist-guided interventions, especially those with synchronous online interaction, produced greater improvements than unguided ones. The analysis reports moderate effect sizes for both anxiety and depression. The authors note that medium- to long-term efficacy requires further validation through high-quality research.
Frontiers in Pharmacology
January 1, 2026
Yang Qu, Shujin Li, Li Tian et al.
A meta-analysis of nine randomized controlled trials involving 1,449 patients found that esketamine improves symptoms in treatment-resistant depression but significantly increases dose-dependent adverse events. Compared with controls, esketamine raised the risk of nine adverse events including nausea, dissociation, dizziness, vertigo, elevated blood pressure, and somnolence. Risks were strongly dose-dependent: the high-dose group (≥56 mg or 0.40 mg/kg) had a greater risk than the low-dose group (≤28 mg or 0.20 mg/kg), with relative risk for nausea of 3.72 versus 1.69 and for dissociation of 10.65 versus 3.27. Although esketamine improved clinical response rate (relative risk = 1.94), it increased treatment discontinuation due to adverse events by 2.22-fold. Clinical use should adopt personalized dosing strategies balancing efficacy and tolerability.
Annals of medicine
December 1, 2026
Zheping Chen, Yaozhu Wang, Peilin Cong et al.
A double-blind randomized trial found that perioperative sub-anesthetic esketamine reduced postoperative depression and anxiety and improved sleep quality in patients undergoing acoustic neuroma surgery. The incidence of depression on postoperative day 1 was 7.7% in the esketamine group versus 31.6% in the placebo group, and on day 3 it was 0.0% versus 15.8%. Anxiety and sleep disturbances also significantly decreased. No significant differences were observed in immune function, postoperative pain scores, or adverse events between groups.
Journal of Psychosomatic Research
December 27, 2019
Congyan Xie, B. Dong, Lihong Wang et al.
A meta-analysis of 14 randomized controlled trials involving 3,008 cancer patients found that mindfulness-based stress reduction (MBSR) significantly reduces cancer-related fatigue, especially in lung cancer patients. An 8-week, expert-supervised MBSR program had a large effect on fatigue compared with usual care or no intervention. MBSR is an effective complementary therapy for managing cancer-related fatigue.